DOI QR코드

DOI QR Code

Development of an Alternative Analytical Method without Related Substance Reference Standards for Fenofibrate in Korean Pharmacopoeia

페노피브레이트 유연물질 표준품 대체시험법 개발

  • Kim, Jung Hyun (Ministry of Food and Drug Safety, National Institute of Food and Drug Safety Evaluation, Drug Research Division) ;
  • Kim, Min Young (Ministry of Food and Drug Safety, National Institute of Food and Drug Safety Evaluation, Drug Research Division) ;
  • Kwon, Eun Kyung (Ministry of Food and Drug Safety, National Institute of Food and Drug Safety Evaluation, Drug Research Division) ;
  • Lee, Kwang Moon (Ministry of Food and Drug Safety, National Institute of Food and Drug Safety Evaluation, Drug Research Division) ;
  • Choi, Don Woong (Ministry of Food and Drug Safety, National Institute of Food and Drug Safety Evaluation, Drug Research Division)
  • 김정현 (식품의약품안전처 식품의약품안전평가원 의약품연구과) ;
  • 김민영 (식품의약품안전처 식품의약품안전평가원 의약품연구과) ;
  • 권은경 (식품의약품안전처 식품의약품안전평가원 의약품연구과) ;
  • 이광문 (식품의약품안전처 식품의약품안전평가원 의약품연구과) ;
  • 최돈웅 (식품의약품안전처 식품의약품안전평가원 의약품연구과)
  • Received : 2015.03.12
  • Accepted : 2015.05.31
  • Published : 2015.06.30

Abstract

Analytical method for related substances can be categorized into two methods depending on the necessity of reference standard (RS). The analytical method of related substances with RS is fast and accurate, but it's very expensive and technically difficult to synthesize RS due to their complicated structure. Another method is using relative retention time (RRT) and relative response factor (RRF) which are already validated with RS. Validation of this method is not easy and time consuming, but once it has been developed, it can save cost and time. In this study, we developed the analytical method for related substances of fenofibrate using RRT and RRF. We validated the method by evaluating specificity, linearity, accuracy and precision according to the "Manual for Guideline Application for Validation of Analytical Procedures" of MFDS. Also, we calculated RRT and RRF between fenofibrate and fenofibrate related substances. The results of this study showed high specificity for fenofibrate and fenofibrate related substances. Correlation coefficient(r) of all substances were more than 0.99, and the recovery of fenofibrate, fenofibrate related substance I, II and III were 99.44%, 100.84%, 99.14% and 101.58%, respectively. Precision of fenofibrate and its related substances were ranged between RSD 0.29% and 0.93%. Quantification limits of fenofibrate, fenofibrate related substance I, II and III were determined to be $0.03{\mu}g/ml$, $0.05{\mu}g/ml$, $0.04{\mu}g/ml$ and $0.02{\mu}g/ml$, respectively by confirming signal to noise ratio of each chromatogram. The RRT for fenofibrate related substance I, II and III were determined to be 0.35, 0.41 and 1.34, respectively. Also, the RRF for fenofibrate related substance I, II and III were determined to be 1.28, 0.98 and 0.79, respectively. The developed method was applied to determine contents for fenofibrate related substances in commercial fenofibrate (active pharmaceutical ingredient). As a result, developed analytical methods of related substances will be used for revising the monograph of fenofibrate in Korean Pharmacopoeia revision and contribute quality control of drugs by improving cost and time consuming problem of RS.

Keywords

References

  1. 대한민국약전 제11개정 (2014).
  2. Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E. and Fruchart, J.-C. : Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98, 2088 (1998). https://doi.org/10.1161/01.CIR.98.19.2088
  3. Abourbih, S., Filion, K. B., Joseph, L., Schiffrin, E. L., Rinfret, S., Poirier, P., Pilote, L., Genest, J. and Eisenberg, M. J. : Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am. J. Med. 122, 962.e1 (2009). https://doi.org/10.1016/j.amjmed.2009.03.030
  4. Shah, A., Rader, D. J. and Millar, J. S. : The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Atheroscler. 210, 35 (2010). https://doi.org/10.1016/j.atherosclerosis.2009.11.010